How EPR financing works
From products to cleaner water. Explore the four steps.
Step explained: Responsibility starts with the product
Medicine and cosmetics producers contribute to removing micropollutants left by their products in wastewater.
Which products does the system cover?
The system covers human medicinal and cosmetic products and micropollutants from these products and their residues.
Overview
Producers of medicinal and cosmetic products must finance at least 80% of the costs required for quaternary treatment, subject to the Directive’s rules.
This interpretation explains how the topic fits into the recast Urban Wastewater Treatment Directive and why it matters for the Czech implementation process. The decisive unit, threshold or timetable must always be read together with the relevant definitions and annexes.
Requirements under the Directive
The Directive connects the legal requirement with measurable environmental and operational outcomes. The following points are central to this topic:
- Contributions should reflect the quantity and hazardousness of products placed on the market.
- Producer responsibility organisations may perform collective obligations.
- The system must cover investment and operating costs while remaining transparent.
Compliance therefore requires more than a formal decision: the underlying data, assumptions, technical solution and monitoring results must remain traceable.
Practical preparation
Owners, operators and public authorities should first confirm the relevant boundaries, loads, permits, receiving-water conditions and available monitoring data. Gaps should be recorded together with responsibility and a date for resolution.
- Document the current technical and legal baseline.
- Identify decisions and investments that depend on Czech implementing rules.
- Connect the topic to the National Implementation Programme and the relevant project timetable.
Czech implementation note
The final allocation of responsibilities, national procedures and project priorities may depend on Czech implementing legislation and the National Implementation Programme. The Czech approach should retain the Directive’s environmental objective while making the evidence and decision process reproducible.
This page will follow those decisions as they are adopted. Until then it is an accessible working interpretation, not a substitute for the legal text or a binding decision by the competent authority.
Summary
Producers of medicinal and cosmetic products must finance at least 80% of the costs required for quaternary treatment, subject to the Directive’s rules.
The practical next step is to verify how the topic applies to the specific agglomeration, collecting system or treatment plant and to keep the supporting evidence ready for planning, permitting and reporting.